At close: June 12 at 4:00 PM EDT
After hours: June 12 at 7:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 12 | 14 |
| Avg. Estimate | -0.03 | 1.08 | 3.98 | 11.7 |
| Low Estimate | -0.43 | 0.04 | 0.9 | 1.33 |
| High Estimate | 0.45 | 2.59 | 6.3 | 25.35 |
| Year Ago EPS | -0.27 | -0.46 | -5.8 | 3.98 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 15 | 19 | 19 |
| Avg. Estimate | 390.69M | 516.45M | 1.94B | 2.93B |
| Low Estimate | 365.6M | 415.5M | 1.66B | 1.8B |
| High Estimate | 463M | 705.54M | 2.42B | 4.4B |
| Year Ago Sales | 261.24M | 331.82M | 1.24B | 1.94B |
| Sales Growth (year/est) | 49.60% | 55.60% | 56.10% | 50.90% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.78 | -1.23 | 0.01 | -0.07 |
| EPS Actual | -0.27 | -0.46 | 0.47 | 0.37 |
| Difference | 1.51 | 0.77 | 0.46 | 0.44 |
| Surprise % | 84.80% | 62.60% | 4,600.00% | 628.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.03 | 1.08 | 3.98 | 11.7 |
| 7 Days Ago | -0.03 | 1.08 | 3.98 | 11.7 |
| 30 Days Ago | -0.06 | 1.07 | 3.61 | 11.54 |
| 60 Days Ago | -0.07 | 0.73 | 2.43 | 11.04 |
| 90 Days Ago | -0.06 | 0.72 | 2.37 | 10.95 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | -- | 1 | 3 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 1 | 1 | 2 |
Growth Estimates
| CURRENCY IN USD | SRPT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 88.90% | -- | -- | 8.40% |
| Next Qtr. | 334.80% | -- | -- | 11.00% |
| Current Year | 168.60% | -- | -- | 5.10% |
| Next Year | 194.00% | -- | -- | 12.00% |
| Next 5 Years (per annum) | 96.00% | -- | -- | 11.33% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Piper Sandler: Overweight | 5/31/2024 |
| Downgrade | RBC Capital: Outperform to Sector Perform | 5/28/2024 |
| Reiterates | Needham: Buy to Buy | 5/20/2024 |
| Maintains | Mizuho: Buy to Buy | 5/17/2024 |
| Upgrade | Oppenheimer: Perform to Outperform | 5/14/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 5/3/2024 |
Related Tickers
JAZZ Jazz Pharmaceuticals plc
111.02
+0.53%
MDGL Madrigal Pharmaceuticals, Inc.
285.83
-2.11%
CYTK Cytokinetics, Incorporated
54.04
+1.41%
BMRN BioMarin Pharmaceutical Inc.
84.55
+0.81%
ALNY Alnylam Pharmaceuticals, Inc.
159.04
+1.67%
INCY Incyte Corporation
59.94
+0.77%
KRYS Krystal Biotech, Inc.
181.96
+2.52%
SAGE Sage Therapeutics, Inc.
10.85
+2.36%
AXSM Axsome Therapeutics, Inc.
71.55
+0.68%
JANX Janux Therapeutics, Inc.
42.75
+1.69%